Vesugen

What is Vesugen?

Vesugen is a synthetic tripeptide consisting of lysine, glutamic acid, and aspartic acid (Lys-Glu-Asp, or KED), developed by Vladimir Khavinson as part of his bioregulator peptide system. It is classified as a Cytogen — a lab-synthesized short peptide designed to mirror the regulatory effects of peptides naturally found in vascular tissue. Originally derived from animal aorta, Vesugen targets vascular endothelial cells and has been studied in Russian clinical settings for atherosclerosis, peripheral vascular disease, and age-related cardiovascular decline. With 27 indexed PubMed publications, it is one of the better-studied Khavinson bioregulators.

What Vesugen Is Investigated For

Vesugen is investigated for vascular protection, endothelial dysfunction in aging, atherosclerosis, vasculogenic erectile dysfunction, and broader anti-aging effects within the Khavinson bioregulator framework. It is one of the better-published Russian bioregulators with 27+ indexed PubMed papers, and the strongest available evidence is a mix of in vitro endothelial cell work showing normalization of endothelin-1 and E-selectin, enhanced sirtuin-1, and Ki-67 upregulation, plus small Russian clinical reports including a 41-man vasculogenic ED study and a 32-patient chronic polymorbidity study. The honest caveats are substantial. Virtually all mechanistic and clinical claims trace to Khavinson-affiliated investigators, Western laboratory replication of the KED-DNA docking interaction is essentially absent, and the Russian clinical reports do not meet modern RCT-methodology standards. The claim that KED (vascular-tropic) and its near-identical sibling KEDA/Livagen (hepatic-tropic) have distinct tissue specificity despite sharing three amino acids lacks independent mechanistic validation. Vesugen's claimed Ki-67 upregulation in vascular tissue is theoretically concerning in oncology contexts and is mechanistically the wrong direction for patients with active malignancy or on anti-angiogenic therapy.

History & Discovery

Vesugen emerged from the bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology, where Vladimir Khavinson and colleagues spent decades fractionating animal-tissue extracts (in this case, calf and porcine aorta) into progressively shorter peptide sequences they claimed retained organ-specific biological activity. Vesugen is the synthetic Cytogen counterpart to the cruder vascular-tissue Cytomax preparation Ventfort, with the active sequence reduced to the tripeptide Lys-Glu-Asp (KED). It shares a backbone with Livagen (KEDA), differing only in a C-terminal alanine — and the Khavinson group's claim that these near-identical sequences nonetheless exhibit distinct tissue tropism (vascular vs. hepatic) is one of the more contentious claims of the entire bioregulator framework. Vesugen sits among the better-published Russian bioregulators, with several dozen indexed papers spanning in vitro endothelial models, molecular docking studies of the KED sequence at the MKI67 promoter, and small Russian clinical reports on vasculogenic erectile dysfunction and chronic limb ischemia in elderly patients. The footprint is, however, almost entirely concentrated within Khavinson-affiliated laboratories and Russian-language clinical settings; independent Western replication of the in vitro epigenetic mechanism, let alone the clinical effect sizes, is essentially absent.

How It Works

Vesugen is a small three-amino-acid peptide that targets blood vessel cells. It is proposed to enter cell nuclei and turn on genes that keep blood vessels healthy — particularly genes involved in cell renewal and reducing inflammation. As we age, these vascular maintenance genes can become silenced, and Vesugen may help reactivate them.

Vesugen (Lys-Glu-Asp) is proposed to penetrate cell membranes and interact directly with DNA and histone proteins in vascular endothelial cells. Research demonstrates several molecular targets: it normalizes endothelin-1 expression (elevated in atherosclerosis), restores connexin-mediated cell-cell communication, and enhances sirtuin-1 expression involved in DNA repair. It stimulates Ki-67 proliferation marker expression while reducing p53 and E-selectin (an adhesion molecule involved in atherosclerotic plaque formation). In aging cell cultures, Vesugen specifically induces differentiation factors CXCL12, Hoxa3, and WEGC1, with effects more pronounced in late-passage (aged) cultures. Molecular docking studies show it contacts the MKI67 gene promoter at positions -14 to +12 relative to the transcription start site, supporting an epigenetic mechanism of action. It also modulates expression of senescence markers (p16, p21) and neurogenesis-related genes (nestin, GAP43) in neural tissue.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Vesugen:

• 01Independent replication outside the Khavinson research program — nearly every mechanistic and clinical claim traces to Khavinson-affiliated investigators. Western laboratory replication of the KED-DNA docking interaction and the in vitro endothelial effects is essentially absent.
• 02Pharmacokinetics in humans — absorption (particularly oral and sublingual bioavailability of a tripeptide), distribution to vascular endothelium, and clearance have not been characterized in humans across routes.
• 03Tissue-specificity mechanism — the claim that KED targets vascular endothelium while the near-identical KEDA targets liver/immune tissue lacks a convincing mechanistic explanation and demands independent validation.
• 04Blinded randomized controlled trials for vascular endpoints — the existing Russian clinical reports on chronic limb ischemia and vasculogenic erectile dysfunction do not meet modern RCT-methodology standards.
• 05Long-term safety in the context of proliferation-marker upregulation — chronic Ki-67 activation in vascular tissue has not been studied for off-target proliferative effects.
• 06Comparative efficacy versus first-line vascular pharmacotherapy — no head-to-head studies against statins, antiplatelets, ACE inhibitors, or PDE5 inhibitors exist.

Forms & Administration

Vesugen is available in capsule, sublingual, and injectable formats. Capsule protocols typically involve 1-2 capsules daily for 10-30 days. Injectable protocols use 10-20 mg per week subcutaneously. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Vesugen is not FDA-approved for any indication. Vascular and erectile-dysfunction claims significantly exceed what the available evidence supports and should not be substituted for evaluation by a clinician familiar with cardiovascular and urologic disease.

Timeline of Effects

Common Questions

Who Vesugen Is NOT For

Drug & Supplement Interactions

There are no documented clinical drug interactions for Vesugen because there are no human pharmacovigilance studies of meaningful scale. What follows is theoretical. The most plausible mechanistic concern is with anti-angiogenic and anti-proliferative oncology agents (bevacizumab, VEGF-pathway tyrosine kinase inhibitors, certain cytotoxic chemotherapies), where Vesugen's claimed activation of vascular endothelial proliferation would be expected to oppose the intended therapeutic effect. A second, more speculative concern is with antihypertensives and nitrate-class vasodilators, given Vesugen's claimed modulation of endothelin-1 and the broader vascular tone signaling environment — but the magnitude in humans is unknown. No CYP-mediated interactions are described, and at the small doses involved, pharmacokinetic interactions at the metabolism level are unlikely. Patients on cardiovascular medication should disclose Vesugen use to their prescribing clinician; absence of documented interaction is not the same as absence of interaction.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions